Kristie L. Kahl

Researchers found significant gender and role differences regarding cardiovascular disease incidence and its related health behaviors among cancer survivors and their spouses.

Nurses can help manage post-traumatic stress disorder symptoms in survivors of non-muscle invasive bladder cancer.

Despite increased physical activity, nutritional intake behavior among female cancer survivors did not improve with an exercise intervention program, according to a randomized, controlled trial.

Nurses play a key role in nurses can play in raising awareness and educating others about a disease that is often not talked about.

Ninety percent of patients with cancer enter their first oncology appointment with a nutritional issue, according to Susan Bratton. However, Savor Health, who works in conjunctions with Merck’s Your Cancer Game Plan, has set out to combat just that.

The FDA approved the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying patients with triple-negative breast cancer who are eligible for treatment with Tecentriq (atezolizumab) plus chemotherapy.

Rivaroxaban (Xarelto) significantly lowered the incidence of venous thromboembolism (VTE) or death due to VTE during the intervention period with the agent in patients with solid tumors or lymphoma, according to results from the CASSINI trial.

A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non-small cell lung cancer at a similar rate but faster turnaround time to that of tissue genotyping.

The FDA granted a priority review to ivosidenib (Tibsovo) for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation who are not eligible for standard therapy.

The FDA granted a priority review to polatuzumab vedotin in combination with bendamustine plus rituximab (Rituxan) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The FDA granted a priority review to entrectinib for the treatment of adult and pediatric patients with NTRK fusion-positive, locally advanced or metastatic solid tumors and for metastatic, ROS1-positive non-small cell lung cancer.

The FDA granted a priority review to pembrolizumab (Keytruda) in combination with axitinib (Inlyta) as a frontline treatment for advanced renal cell carcinoma.

Oncology Nursing News® spoke with CEO Linda Tantawi about addressing the needs of underserved communities and nurses can help to educate women in the Greater New York City area.

The FDA granted a priority review to avelumab (Bavencio) in combination with axitinib (Inlyta) to treat patients with advanced renal cell carcinoma (RCC).

The FDA granted a priority review to the supplemental biologics license application for pembrolizumab (Keytruda) for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Treatment with rivaroxaban (Xarelto) may reduce the risk for developing blood clots during active treatment with a systemic therapy like chemotherapy, according to results from the CASSINI trial.

The FDA approved tagraxofusp-erzs (Elzonris) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients aged 2 or older.

Oxybutynin helped to improve quality of life among women who could not take hormone replacement therapy in survivorship by reducing the frequency and intensity of hot flashes.

Treatment with luspatercept significantly reduced the need for frequent red blood cell transfusions in nearly 53% of patients with anemia associated with low- to intermediate-risk myelodysplastic syndrome (MDS), according to results from the phase III Medalist trial presented at the 2018 ASH Annual Meeting.

Hematologists may have the ability to determine acute myeloid leukemia (AML) subtype based on genetic analysis of blood samples in 7 days or less, a process that could soon be an integral part of diagnosing and treating this patient population, according to Amy Burd, PhD.

Receiving a stem cell transplant for the first time following CD19 CAR T-cell therapy induced a reduction in the risk for acute lymphoblastic leukemia (ALL) recurrence, according to a retrospective analysis of the phase I/II PLAT-02 study.1

To best manage lymphedema, patients must first have an under­standing of their disease, no matter what its type.

The FDA has granted a priority review designation to atezolizumab (Tecentriq) for use in combination with carboplatin and etoposide for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

To receive payment for counseling and increase access to services, a new bill has been introduced so that genetic counselors receive payment for counseling Medicare beneficiaries.

Patients with renal cell carcinoma (RCC) who were treated with tivozanib (Fotivda) experienced a 26% reduction in the risk of progression or death compared with sorafenib (Nexavar), according to results from the phase 3 TIVO-3 trial.

The Food and Drug Administration (FDA) granted a priority review to atezolizumab (Tecentriq) in combination with nab-paclitaxel (Abraxane) for frontline use in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose disease expresses the PD-L1 protein.

The Food and Drug Administration approved pegfilgrastim-cbqv (Udenyca), a biosimilar to pegfilgrastim (Neulasta).

The Food and Drug Administration has granted a priority review to the supplemental new drug application for ruxolitinib (Jakafi) to treat patients with acute graft-versus-host-disease (GVHD) who have had an inadequate response to corticosteroids.

The Food and Drug Administration (FDA) approved Khapzory (levoleucovorin) injection, a folate analog for 3 indications.

Durvalumab (Imfinzi) induced a clinically meaningful improvement in overall survival (OS) compared with placebo in patients with stage III, unresectable non–small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy.